Anton , S. F. & Revicki , D. A. ( 1995 ) The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone . Psychopharmacology Bulletin , 31 , 249 – 258 .

Australian Government ( 1995 ) Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submissions Involving Economic Analysis . Canberra : Australian Government Publishing Service .

Azimi , N. A. & Welch , G. H. ( 1998 ) The effectiveness of cost-effectiveness analysis in containing costs . Journal of General Internal Medicine , 13 , 664 – 669 .

Bentkover , J. D. & Feighner , J. P. ( 1996 ) Cost analysis of paroxetine vs imipramine in major depression . Pharmacoeconomics , 8 , 223 – 232 .

Borghi , J. & Guest , J. F. ( 2000 ) Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK . European Psychiatry , 15 , 378 – 387 .

Boyer , P. , Danion , J. M. , Bisserbe , J. C. , et al ( 1998 ) Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression . Pharmacoeconomics , 13 , 157 – 169 .

Brown , M. C. , Nimmerrichter , A. A. & Guest , J. F. ( 1999a ) Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria . European Psychiatry: Journal of the Association of European Psychiatrists , 14 , 230 – 244 .

Brown , M. C. , van Loon , J. M. T. & Guest , J. F. ( 1999b ) Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France . European Journal of Psychiatry , 13 , 197 – 208 .

Canadian Coordinating Office for Health Technology Assessment ( 1994 ) Guidelines for Economic Evaluation of Pharmaceuticals . Ottawa : CCOHTA .

Canadian Coordinating Office for Health Technology Assessment ( 1998 ) Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II: The cost effectiveness of SSRIs in treatment of depression. August 1997. Report 4E . Evidence-Based Medicine , 3 , 87 .

Casciano , J. , Doyle , J. , Arikian , S. , et al ( 2001 ) The health economic impact of antidepressant usage from a payer's perspective: a multinational study . International Journal of Clinical Practice , 55 , 292 – 299 .

Cook , J. R. ( 1999 ) Challenges in economic outcomes research . Hepatology , 29 , 23S – 25S .

Croghan , T. W. , Lair , T. J. , Engelhart , L. , et al ( 1997 ) Effect of antidepressant therapy on health care utilization and costs in primary care . Psychiatric Services , 48 , 1420 – 1426 .

Croghan , T. W. , Kniesner , T. J. , Melfi , C. A. , et al ( 2000 ) Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals . Administration and Policy in Mental Health , 27 , 183 – 195 .

Crown , W. H. , Hylan , T. R. & Meneades , L. ( 1998 ) Antidepressant selection and use and healthcare expenditures – an empirical approach . Pharmacoeconomics , 13 , 435 – 448 .

Davidson , R. A. ( 1986 ) Source of funding and outcome of clinical trials . Journal of General Internal Medicine , 1 , 155 – 158 .

Detsky , A. S. ( 1994 ) Using cost-effectiveness analysis for formulary decision making: from theory into practice . Pharmacoeconomics , 6 , 281 – 288 .

Djulbegovic , B. , Lacevic , M. , Cantor , A. , et al ( 2000 ) The uncertainty principle and industry-sponsored research . Lancet , 356 , 635 – 638 .

Doyle , J. J. , Casciano , J. , Arikian , S. , et al ( 2001 ) A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD); a comparison of cost-effectiveness between venlafaxine, SSRIs, and TCAs . Value in Health , 4 , 16 – 31 .

Drummond , M. F. ( 1998 ) A reappraisal of economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics , 14 , 1 – 9 .

Einarson , T. R. , Arikian , S. , Sweeney , S. , et al ( 1995 ) A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders . Clinical Therapeutics , 17 , 136 – 153 .

Einarson , T. R. , Addis , A. & Iskedjian , M. ( 1997 ) Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder . Pharmacoeconomics , 12 , 286 – 296 .

Forder , J. , Kavanagh , S. & Fenyo , A. ( 1996 ) A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care . Journal of Affective Disorders , 38 , 97 – 111 .

Freemantle , N. & Mason , J. ( 1997 ) Publication bias in clinical trials and economic analyses Pharmacoeconomics , 12 , 10 – 16 .

Friedberg , M. , Saffran , B. , Stinson , T. J. , et al ( 1999 ) Evaluation of conflict of interest in economic analyses of new drugs used in oncology . JAMA , 282 , 1453 – 1475 .

Gagnon , J. P. ( 2000 ) Sources of bias in the economic analysis of new drugs (letter) . JAMA , 283 , 1423 .

Griffiths , R. I. , Sullivan , E. M. , Frank , R. G. , et al ( 1999 ) Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy . Pharmacoeconomics , 15 , 495 – 505 .

Gulati , S. C. & Bitran , J. D. ( 1995 ) Cost-effectiveness analysis: sleeping with an enemy or a friend? Journal of Clinical Oncology , 13 , 2152 – 2154 .

Hatziandreu , E. J. , Brown , R. E. , Revicki , D. A. , et al ( 1994 ) Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin . Pharmacoeconomics , 5 , 249 – 264 .

Hill , S. R. , Mitchell , A. S. & Henry , D. A. ( 2000 ) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme . JAMA , 283 , 2116 – 2121 .

Hillman , A. L. , Eisenberg , J. M. , Pauly , M. V. , et al ( 1991 ) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies New England Journal of Medicine , 324 , 1362 – 1365

Hillman , B. J. , Joseph , C. A. , Magel , M. R. , et al ( 1990 ) Frequency and costs of diagnostic imaging in office practice: a comparison of self referring and radiologist referring physicians New England Journal of Medicine , 323 , 1504 – 1508

Hotopf , M. , Lewis , G. & Normand , C. ( 1996 ) Are SSRIs a cost-effective alternative to tricyclics? British Journal of Psychiatry , 168 , 404 – 409

Hylan , T. R. , Kotsanos , J. G. , Andersen , J. S. , et al ( 1996 ) Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application of evaluating alternative antidepressants American Journal of Managed Care , 2 , 1211 – 1223

Hylan , T. R. , Crown , W. H. , Meneades , L. , et al ( 1998 ) Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis Journal of Affective Disorders , 47 , 71 – 79

IMS Health ( 2001 ) The global pharmaceutical market in 2000 . www.ims-global.com/insight/news_story/0103/news=story=010314.htm.

Jones , M. T. & Cockrum , P. C. ( 2000 ) A critical review of published economic modelling studies in depression . Pharmacoeconomics , 17 , 555 – 583 .

Jonsson , B. & Bebbington , P. ( 1993 ) Economic studies of the treatment of depressive illness . In Health Economics of Depression (eds Jonsson , B. & Rosenbaum , J. ), pp. 35 – 48 . Chichester : John Wiley .

Jonsson , B. & Bebbington , P. ( 1994 ) What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment . British Journal of Psychiatry , 164 , 665 – 673 .

Lapierre , Y. , Bentkover , J. , Schainbaum , S. , et al ( 1995 ) Direct costs of depression: analysis of treatment costs of paroxetine versus imipramine in Canada . Canadian Journal of Psychiatry , 40 , 370 – 377 .

Laupacis , A. , Feeny , D. , Detsky , A. S. , et al ( 1992 ) How attractive does a new technology have to be to warrant adoption and utilization? Canadian Medical Association Journal , 146 , 473 – 481 .

Le Pen , C. , Levy , E. , Ravily , V. , et al ( 1994 ) The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. tricyclics . Journal of Affective Disorders , 31 , 1 – 18 .

Luce , B. R. ( 1995 ) Policy implications of modelling the cost-effectiveness of health care technologies . Drug Information Journal , 29 , 1469 – 1475 .

Mandelkern , M. ( 1999 ) Manufacturer support and outcome (letter) . Journal of Clinical Psychiatry , 60 , 122 .

Maynard , A. & Cookson , R. F. ( 1998 ) Computer modelling: the need for careful evaluation and public audit . Pharmacoeconomics , 14 , 67 – 72 .

McCabe , C. & Dixon , S. ( 2000 ) Testing the validity of cost-effectiveness models . Pharmacoeconomics , 17 , 501 – 513 .

McFarland , B. H. ( 1994 ) Cost-effectiveness considerations for managed care systems: treating depression in primary care . American Journal of Medicine , 97 ( suppl. 6A ), 47S – 58S .

Melton , S. T. , Kirkwood , C. K. , Farrar , T. W. , et al ( 1997 ) Economic evaluation of paroxetine and imipramine in depressed outpatients . Psychopharmacology Bulletin , 33 , 93 – 100 .

Montgomery , S. A. , Brown , R. E. & Clark , M. ( 1996 ) Economic analysis of treating depression with nefazodone v. imipramine . British Journal of Psychiatry , 168 , 768 – 771 .

Neumann , P. J. ( 1998 ) Paying the piper for pharmacoeconomic studies . Medical Decision Making , 18 , S23 – 26 .

Neumann , P. J. , Sandberg , E. A. , Bell , C. , et al ( 2000a ) Are pharmaceuticalls cost-effective? A review of the evidence . Health Affairs , 19 , 92 – 109 .

Neumann , P. J. , Stone , P. W. , Chapman , R. H. , et al ( 2000b ) The quality of reporting in published cost–utility analyses, 1976–1997 . Annals of Internal Medicine , 132 , 964 – 972 .

Nuijten , M. J. C. , Hardens , M. & Soutre , E. ( 1995 ) A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression . Pharmacoeconomics , 8 , 159 – 168 .

Nurnberg , G. H. , Hensley , P. L. , Thompson , P. M. , et al ( 1999 ) Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors . Psychiatric Services , 50 , 1351 – 1353 .

Obenchain , R. L. , Melfi , C. A. , Croghan , T. W. , et al ( 1997 ) Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy . Pharmacoeconomics , 11 , 464 – 472 .

O'Brien , B. ( 1996 ) Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Medical Care , 34 , DS99–108.

Ontario Ministry of Health ( 1994 ) Ontario Guidelines for Economic Analysis of Pharmaceutical Products . Toronto : Ontario Ministry of Health, Drug Programs Branch .

Poret , A. W. , Neslusan , C. , Ricci , J. , et al ( 2001 ) Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants . Value in Heallth , 4 , 362 – 369 .

Rennie , D. & Flanagin , A. ( 1992 ) Publication bias: the triumph of hope over experience . JAMA , 267 , 411 – 412 .

Rennie , D. & Luft , H. S. ( 2000 ) Pharmacoeconomic analyses: making them transparent, making them credible . JAMA , 283 , 2158 – 2160 .

Revicki , D. A. , Brown , R. E. , Palmer , W. , et al ( 1995 ) Modelling the cost effectiveness of antidepressant treatment in primary care . Pharmacoeconomics , 8 , 524 – 540 .

Revicki , D. A. , Brown , R. E. , Keller , M. B. , et al ( 1997 ) Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings . Journal of Clinical Psychiatry , 58 , 47 – 58 .

Rochon , P. A. , Gurwitz , J. H. , Simms , R. W. , et al ( 1994 ) A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis . Archives of Internal Medicine , 154 , 157 – 163 .

Russell , J. M. , Berndt , E. R. , Miceli , R. , et al ( 1999 ) Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline . American Journal of Managed Care , 5 , 597 – 606 .

Sacristan , J. A. , Bolanos , E. , Soto , J. , et al ( 1997 ) Publication bias in health economic studies (letter) . Pharmacoeconomics , 11 , 289 – 290 .

Sclar , D. A. , Robison , L. M. , Skaer , T. L. , et al ( 1994 ) Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization . Clinical Therapeutics , 16 , 715 – 730 .

Sclar , D. A. , Robison , L. M. , Skaer , T. L. , et al ( 1995 ) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization . Journal of International Medical Research , 23 , 395 – 412 .

Sclar , D. A. , Skaer , T. L. , Robison , L. M. , et al ( 1998 ) Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis . Journal of Clinical Psychiatry , 59 , 13 – 17 .

Sclar , D. A. , Skaer , T. L. , Robison , L. M. , et al ( 1999 ) Economic appraisal of citalopram in the management of single-episode depression . Journal of Clinical Psychopharmacology , 19 , 47S – 54S .

Sheldon , T. A. ( 1996 ) Problems of using modelling in the economic evaluation of health care . Health Economics , 5 , I – II .

Siegel , J. E. , Weinstein , M. C. , Russell , L. B. , et al ( 1996 ) Recommendations for reporting cost-effectiveness analyses . JAMA , 276 , 1339 – 1341 .

Simon , G. E. & Fishman , P. ( 1998 ) Cost implications of initial antidepressant selection in primary care . Pharmacoeconomics , 13 , 61 – 70 .

Simon , G. E. , Heilegenstein , J. H. , Revicki , D. A. , et al ( 1999 ) Long-term outcomes of initial antidepressant drug choice in a ‘real world’ randomized trial . Archives of Family Medicine , 8 , 319 – 325 .

Skaer , T. L. , Sclar , D. A. , Robison , L. M. , et al ( 1995 ) Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression . Current Therapeutic Research , 56 , 556 – 567 .

Smith , W. & Sherrill , A. ( 1996 ) A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO . Medical Interface , 9 , 88 – 92 .

Stelfox , H. T. , Chua , G. , O'Rourke , K. , et al ( 1998 ) Conflict of interest in the debate over calcium-channel antagonists . New England Journal of Medicine , 338 , 101 – 106 .

Stewart , A. ( 1994 ) Anti-depressant pharmacotherapy: cost comparison of SSRIs and TCAs . British Journal of Medical Economics , 7 , 67 – 79 .

Sullivan , E. M. , Griffiths , R. I. , Frank , R. G. , et al ( 2000 ) One-year costs of second-line therapies for depression . Journal of Clinical Psychiatry , 61 , 290 – 298 .

Thompson , D. , Hylan , T. R. , McMullen , W. , et al ( 1998 ) Predictors of a medical-offset effect among patients receiving antidepressant therapy . American Journal of Psychiatry , 155 , 824 – 827 .

Udrarhelyi , I. S. , Graham , A. , Rai , A. , et al ( 1992 ) Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Annals of Internal Medicine , 116 , 238 – 244 .

Wan , G. J. , Crown , W. H. , Berndt , E. R. , et al ( 2002 ) Treatment costs of venlafaxine and selective serotoninreuptake inhibitors for depression and anxiety . Managed Care Interface , 15 , 24 – 30 .

Woods , S. W. & Baker , C. B. ( 1997 ) Cost-effectiveness of newer antidepressants . Current Opinion in Psychiatry , 10 , 95 – 101 .

Woods , S. W. & Baker , C. B. ( 2002 ) Cost effectiveness of the newer generation of antidepressants . In Psychopharmacology: The Fifth Generation of Progress (eds Davis , K. L. , Coyle , J. , Charney , D. S. , et al), pp. 1119 – 1138 . New York : Raven Press .

Woods , S. W. & Rizzo , J. A. ( 1997 ) Cost-effectiveness of antidepressant treatment reassessed . British Journal of Psychiatry , 170 , 257 – 263 .